Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma.
Int J Biol Sci
; 17(2): 448-459, 2021.
Article
in En
| MEDLINE
| ID: mdl-33613104
ABSTRACT
Endometrial carcinoma (EnCa) is one of the deadliest gynecological malignancies. The purpose of the current study was to develop an immune-related lncRNA prognostic signature for EnCa. In the current research, a series of systematic bioinformatics analyses were conducted to develop a novel immune-related lncRNA prognostic signature to predict disease-free survival (DFS) and response to immunotherapy and chemotherapy in EnCa. Based on the newly developed signature, immune status and mutational loading between high and lowrisk groups were also compared. A novel 13-lncRNA signature associated with DFS of EnCa patients was ultimately developed using systematic bioinformatics analyses. The prognostic signature allowed us to distinguish samples with different risks with relatively high accuracy. In addition, univariate and multivariate Cox regression analyses confirmed that the signature was an independent factor for predicting DFS in EnCa. Moreover, a predictive nomogram combined with the risk signature and clinical stage was constructed to accurately predict 1-, 2-, 3-, and 5-year DFS of EnCa patients. Additionally, EnCa patients with different levels of risk had markedly different immune statuses and mutational loadings. Our findings indicate that the immune-related 13-lncRNA signature is a promising classifier for prognosis and response to immunotherapy and chemotherapy for EnCa.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Endometrial Neoplasms
/
RNA, Long Noncoding
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Int J Biol Sci
Journal subject:
BIOLOGIA
Year:
2021
Type:
Article
Affiliation country:
China